Sort
21,281 grants matching “influenza”
Efficacy of Antibiotics in Children with Acute Sinusitis: Which Subgroups Benefit?
$971,785Nader Shaikh · University Of Pittsburgh At Pittsburgh · U01 · FY2019 · AI
Microneedle Delivery of Zanamivir for Treatment of Influenza
$971,504Elke Lipka · Tsrl, Inc. · R44 · FY2020 · AI
Development of Influenza Virus-Like Particle (VLP) Vaccines
$971,080Jose M Galarza · Technovax, Inc. · R44 · FY2010 · AI
HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP
$971,055Jeffery Alexander · Paxvax, Inc. · R44 · FY2016 · AI
Plasma Gelsolin as Immunotherapeutic for Antibiotic-Resistant Pneumonia
$970,844Lester Kobzik · Harvard School Of Public Health · R01 · FY2017 · AI
Engineering Monodisperse Particulate Vaccines to Tailor Immunological Responses
$970,757Jenny P.y. Ting · Univ Of North Carolina Chapel Hill · U19 · FY2016 · AI
Increasing Resilience of Survivor-Centered Social Systems: Adapting to COVID Related Constraints in Access to Services and Built Environment Use Patterns
$970,549Jennifer A Horney · University Of Delaware · · FY2021 · ENG
Incidence and etiology of influenza associated pneumonia in hospitalized children
$970,376Jonathan A McCullers · St. Jude Children'S Research Hospital · U18 · FY2009 · IP
Genomics Core
$969,998John A T Young · Icahn School Of Medicine At Mount Sinai · U19 · FY2015 · AI
COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,
$969,746Ted Ross · University Of Georgia · N01 · FY2020 · AI
Biodefense/Emerging Infection Vaccine Studies
$969,286Barney Scott Graham · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
CMC of Peptide Formulation for the Treatment of ARDS
$967,740Gerardo M. Castillo · Pharmain Corporation · R44 · FY2023 · HL
Pacific Center for Emerging Infectious Diseases Research
$967,630Vivek Ramchandra Nerurkar · University Of Hawaii At Manoa · P30 · FY2022 · GM
CK21-003, Oregon Child Absenteeism due to Respiratory Disease Study - 3
$967,373Jonathan L Temte · University Of Wisconsin-Madison · U01 · FY2021 · CK
Rapid response to pandemic influenza via multi-antigen RNA-based vaccine
$966,637Jasdave Chahal · Tiba Biotech, Llc · R44 · FY2023 · AI
Project 4: Computational panbetaCoV immunogen design
$966,626Rory Henderson · Duke University · P01 · FY2023 · AI
Vaccine Development for Burkholderia amllei and B. pseudomallei
$966,161Alfredo G Torres · University Of Texas Med Br Galveston · U54 · FY2012 · AI
A dual vaccine strategy against filovirus infection
$966,148Richard W Compans · Emory University · R01 · FY2011 · AI
Rapid response to pandemic influenza via multi-antigen RNA-based vaccine
$965,715Jasdave Chahal · Tiba Biotech, Llc · R44 · FY2025 · AI
Rapid response to pandemic influenza via multi-antigen RNA-based vaccine
$965,678Jasdave Chahal · Tiba Biotech, Llc · R44 · FY2024 · AI
Universal room temperature stable influenza nanovaccine
$965,238Balaji Narasimhan · Iowa State University · R01 · FY2023 · AI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.
$964,499Iain James Macleod · Aldatu Biosciences, Inc. · R44 · FY2022 · AI
X-ray Crystallographic Fragment Screening Core
$964,449Edward V Arnold · Scripps Research Institute, The · U54 · FY2017 · GM
Targeting MMP9 to Improve Outcomes in Serious Influenza Infections
$964,377Kevin S Harrod · University Of Alabama At Birmingham · R01 · FY2016 · AI
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
$964,143Roy Curtiss · Arizona State University-Tempe Campus · R01 · FY2013 · AI